Dynamic HALP Score as a Time-Dependent Prognostic Biomarker in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Cancers · 12.05.2026 · 18 (10) · 1570
DOI: 10.3390/cancers18101570 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 12.05.2026. Verfasst von Öznur Aydın und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Faculty of Medicine, Samsun University, Samsun 55080, Türkiye. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives: The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is an immunonutritional biomarker reflecting systemic inflammation, nutritional status, and immune competence. Its dynamic behavior and prognostic relevance in multiple myeloma (MM) following autologous stem cell transplantation (ASCT) remain insufficiently characterized. Materials and Methods: In this retrospective cohort study, 95 MM patients undergoing ASCT were analyzed. HALP scores were calculated at diagnosis and at post-transplant day +100, and dynamic changes (ΔHALP) were assessed. Associations with overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan–Meier and multivariable Cox regression analyses, with maintenance therapy incorporated as a covariate.
Results
During a median follow-up of 50 months (range: 11.0–144.0), 36.8% of patients progressed or relapsed, and 23.2% died. Baseline HALP was associated with both OS and PFS in unadjusted analyses; however, the inverse association at diagnosis was substantially attenuated after adjustment for maintenance therapy (HR: 0.71, 95% CI: 0.28–1.80; p = 0.466). HALP at day +100 showed a robust association with PFS that strengthened after adjustment (HR: 3.27, 95% CI: 1.45–7.38; p = 0.004). The discriminative performance for treatment response was limited, with 95% CIs encompassing AUC = 0.50.
Conclusions
Post-transplant HALP at day +100 emerged as the most robust HALP-based prognostic indicator for PFS. Given the small sample size, limited OS events (n = 22), use of outcome-driven cut-offs, and absence of cytogenetic and minimal residual disease data, dynamic HALP assessment may provide exploratory prognostic information warranting validation in larger, prospective, multi-center cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Faculty of Medicine, Samsun University, Samsun 55080, Türkiye.
- Department of Hematology, Faculty of Medicine, Ondokuz Mayıs University, Samsun 55139, Türkiye.
- Department of Internal Medicine, Samsun City Hospital, Samsun 55080, Türkiye.
ORCID-Profile: Öznur Aydın, Enis Akca
Zitieren
APA
Aydın, Ö., Şahin, O., Akca, E., Kürekci, D. D., Aktimur, S. H., Kelkitli, E., & Turgut, M. (2026). Dynamic HALP Score as a Time-Dependent Prognostic Biomarker in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Cancers, 18(10), 1570. https://doi.org/10.3390/cancers18101570
Vancouver
Aydın Ö, Şahin O, Akca E, Kürekci DD, Aktimur SH, Kelkitli E, et al. Dynamic HALP Score as a Time-Dependent Prognostic Biomarker in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Cancers. 2026;18(10):1570. doi:10.3390/cancers18101570
BibTeX
@article{Aydn2026,
author = {Aydın, Öznur and Şahin, Onur and Akca, Enis and Kürekci, Derya Deniz and Aktimur, Sude Hatun and Kelkitli, Engin and Turgut, Mehmet},
title = {Dynamic HALP Score as a Time-Dependent Prognostic Biomarker in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation},
journal = {Cancers},
year = {2026},
volume = {18},
number = {10},
pages = {1570},
doi = {10.3390/cancers18101570}
}
EUVIMED